We have developed an antithrombin-heparin covalent complex (ATH) which inhibits coagulation enzymes by two mechanisms: directly, or by catalytic activation of plasma antithrombin (AT). Anticoagulation by ATH was compared to unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) using a blood-based, tissue factor (TF)-activated thrombelastography (TEG) assay. Simplified TEG assays with plasma or purified plasma components were used to determine the contribution of the direct and catalytic mechanisms to ATH efficacy. Low anti-Xa concentrations of UFH inhibited clot formation significantly more than equivalent concentrations of ATH or LMWH in blood and plasma. ATH had reduced ability to catalyse AT-mediated thrombin (IIa) inhibition compared to UFH. However, at high anti-Xa concentrations, ATH had similar anticoagulant activity to UFH. ATH and non-covalent AT+UFH directly inhibited clotting to a similar degree in AT-deficient plasma. IIa-ATH complexes, which are limited to catalytic inhibition, displayed impaired anticoagulation compared to free ATH, and the magnitude of this effect increased significantly as anticoagulant concentration increased. Kinetic experiments indicated that the rate of reaction of AT with IIa is lower when catalysed by ATH versus UFH. In conclusion, at low anti-Xa doses catalytic inhibition is the primary mechanism of ATH anticoagulation, and the catalytic potential of ATH is reduced relative to UFH. However, the direct inhibitory activity of ATH is comparable to noncovalent AT+UFH, and at high anti-Xa doses the direct inhibitory activity of ATH may play a larger role in anticoagulation.
5
Chan A,
Berry L,
O’Brodovich H.
et al. Covalent antithrombin-heparin complexes with high anticoagulant activity. Intravenous, subcutaneous and intratracheal administration. J Biol Chem 1997; 272: 22111-22117.
6
Chan AKC,
Rak J,
Berry L.
et al. Antithrombin-heparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention. Circulation 2002; 106: 261-265.
8
Chan AKC,
Paredes N,
Thong B.
et al. Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin. Thromb Haemost 2004; 91: 1009-1018.
9
Patel S,
Berry L,
Chan AKC.
Analysis of inhibition rate enhancement by covalent linkage of antithrombin to heparin as a potential predictor of reaction mechanism. J Biochem 2007; 141: 25-35.
12
Paredes N,
Wang A,
Berry LR.
et al. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex. J Biol Chem 2003; 278: 23398-23409.
14
Coppell JA,
Thalheimer U,
Zambruni A.
et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis 2006; 17: 97-104.
16
Olson ST,
Björk I,
Sheffer R.
et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
17
Chan AKC,
Berry LR,
Monagle P.
et al. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost 2002; 87: 606-613.
19
Berry L,
Stafford A,
Fredenburgh J.
et al. Investigation of the anticoagulation mechanisms of a covalent antithrombin-heparin complex. J Biol Chem 1998; 273: 34730-34736.
20
Gerotziafas GT,
Chakroun T,
Samama MM.
et al.
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost 2004; 92: 1296-1302.
22
Konstantinidis K,
Gerasimidis T,
Verdy E.
et al. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. Thromb Haemost 2007; 97: 109-118.
23
Duchemin J,
Pan-Petesch B,
Arnaud B.
et al. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99: 767-773.
24
So AK,
Varisco P-A,
Kemkes-Matthes B.
et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 01: 2510-2515.
26
Philippou H,
Adami A,
Davidson SJ.
et al. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 2000; 84: 124-128.
27
Oh D,
Kim SH,
Kang MS.
et al. Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus. Am J Hematol 2003; 72: 103-108.
28
Pawlak K,
Pawlak D,
Mysliwiec M.
Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagul Fibrinolysis 2007; 18: 467-471.
29
Paparella D,
Al Radi OO,
Meng QH.
et al. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass. Blood Coag Fibrinolysis 2005; 16: 323-328.
